Insmed Inc (INSM)vsTenaya Therapeutics Inc (TNYA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
TNYA
Tenaya Therapeutics Inc
$0.76
+0.79%
HEALTHCARE · Cap: $163.01M
Smart Verdict
WallStSmart Research — data-driven comparison
TNYA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
TNYA
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : TNYA
The strongest argument for TNYA centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : TNYA
The primary concerns for TNYA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while TNYA is a value play — different risk/reward profiles.
TNYA carries more volatility with a beta of 3.23 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
TNYA generates stronger free cash flow (-14M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Tenaya Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tenaya Therapeutics Inc. is a clinical-stage biotechnology innovator committed to revolutionizing heart disease treatment through its proprietary engineered heart cell platform. The company is addressing significant unmet needs in cardiovascular medicine by developing advanced gene therapies and regenerative solutions, with a robust pipeline of candidates targeting various heart disease indications. Tenaya's scientific rigor and focus on patient outcomes position it as a compelling investment opportunity in the biopharmaceutical sector, appealing to institutional investors seeking to support advancements in cardiac care. Its strategic initiatives underscore the potential for impactful contributions to the evolving landscape of cardiovascular therapies.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?